EED and sarcoma: A significant correlation with poor prognosis was also observed for high EZH2 and SUZ12 expression in sarcoma (Table 1, Figure 5B) and in lung adenocarcinoma (Table 1, Figure 5C); for EZH2 in breast cancer (Table 1, Figure 6A); for EZH2 and EED expression in ovarian cancer (Table 1, Figure 6B).